# A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

> **NCT05498428** · PHASE2 · RECRUITING · sponsor: **Janssen Research & Development, LLC** · enrollment: 520 (estimated)

## Conditions studied

- Carcinoma, Non-small-Cell Lung

## Interventions

- **DRUG:** Amivantamab
- **DRUG:** Lazertinib
- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed
- **DRUG:** Direct Oral Anticoagulant (DOAC)
- **DRUG:** Low Molecular Weight Heparin (LMWH)

## Key facts

- **NCT ID:** NCT05498428
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-11
- **Primary completion:** 2027-08-17
- **Final completion:** 2028-08-18
- **Target enrollment:** 520 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05498428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05498428, "A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT05498428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*